KR100674053B1 - 급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도 - Google Patents

급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도 Download PDF

Info

Publication number
KR100674053B1
KR100674053B1 KR1020017009327A KR20017009327A KR100674053B1 KR 100674053 B1 KR100674053 B1 KR 100674053B1 KR 1020017009327 A KR1020017009327 A KR 1020017009327A KR 20017009327 A KR20017009327 A KR 20017009327A KR 100674053 B1 KR100674053 B1 KR 100674053B1
Authority
KR
South Korea
Prior art keywords
angiotensin
acute
treatment
receptor antagonists
valsartan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017009327A
Other languages
English (en)
Korean (ko)
Other versions
KR20020002379A (ko
Inventor
예시카 엠. 만
빠스칼 오두
에릭 미쉘 노하르뜨
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100674053(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20020002379A publication Critical patent/KR20020002379A/ko
Application granted granted Critical
Publication of KR100674053B1 publication Critical patent/KR100674053B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020017009327A 1999-01-26 2000-01-24 급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도 Expired - Fee Related KR100674053B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
EP99810061.4 1999-01-26
US46866499A 1999-12-21 1999-12-21
US09/468,664 1999-12-21

Publications (2)

Publication Number Publication Date
KR20020002379A KR20020002379A (ko) 2002-01-09
KR100674053B1 true KR100674053B1 (ko) 2007-01-25

Family

ID=26153740

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009327A Expired - Fee Related KR100674053B1 (ko) 1999-01-26 2000-01-24 급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도

Country Status (25)

Country Link
EP (2) EP1714651A1 (https=)
JP (1) JP2002535367A (https=)
KR (1) KR100674053B1 (https=)
CN (1) CN1337879A (https=)
AT (1) ATE330599T1 (https=)
AU (1) AU766453C (https=)
BR (1) BR0007686A (https=)
CA (1) CA2360691A1 (https=)
CY (1) CY1105257T1 (https=)
CZ (1) CZ20012682A3 (https=)
DE (1) DE60028928T2 (https=)
DK (1) DK1146872T3 (https=)
ES (1) ES2265910T3 (https=)
HK (1) HK1041808B (https=)
HU (1) HUP0105199A3 (https=)
ID (1) ID29818A (https=)
IL (2) IL144216A0 (https=)
NO (1) NO20013459L (https=)
NZ (1) NZ513039A (https=)
PL (1) PL197161B1 (https=)
PT (1) PT1146872E (https=)
RU (2) RU2298405C2 (https=)
SI (1) SI1146872T1 (https=)
SK (1) SK10522001A3 (https=)
WO (1) WO2000044378A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304000C (zh) * 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7076287B2 (en) 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
JP2005531558A (ja) * 2002-05-17 2005-10-20 ノバルティス アクチエンゲゼルシャフト 心筋梗塞の二次予防のためのアンギオテンシンＩＩ受容体ブロッカーおよびβブロッカーの組合せ
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010180A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Plc Use of angiotensin ii antagonist in the treatment of infarction
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010180A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Plc Use of angiotensin ii antagonist in the treatment of infarction
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
CY1105257T1 (el) 2010-03-03
SK10522001A3 (sk) 2001-12-03
RU2006135205A (ru) 2008-04-10
NZ513039A (en) 2003-11-28
HK1041808A1 (en) 2002-07-26
EP1146872A1 (en) 2001-10-24
SI1146872T1 (sl) 2006-12-31
ES2265910T3 (es) 2007-03-01
CA2360691A1 (en) 2000-08-03
RU2298405C2 (ru) 2007-05-10
CZ20012682A3 (cs) 2001-10-17
WO2000044378A1 (en) 2000-08-03
HK1041808B (en) 2007-01-19
HUP0105199A3 (en) 2004-11-29
EP1714651A1 (en) 2006-10-25
DK1146872T3 (da) 2006-10-16
DE60028928D1 (de) 2006-08-03
RU2345790C2 (ru) 2009-02-10
NO20013459L (no) 2001-09-05
AU766453C (en) 2004-11-25
AU766453B2 (en) 2003-10-16
DE60028928T2 (de) 2007-01-04
AU2439700A (en) 2000-08-18
IL144216A (en) 2007-07-04
ID29818A (id) 2001-10-11
IL144216A0 (en) 2002-05-23
KR20020002379A (ko) 2002-01-09
PL197161B1 (pl) 2008-03-31
PT1146872E (pt) 2006-10-31
ATE330599T1 (de) 2006-07-15
NO20013459D0 (no) 2001-07-12
HUP0105199A2 (hu) 2002-04-29
BR0007686A (pt) 2001-11-06
CN1337879A (zh) 2002-02-27
JP2002535367A (ja) 2002-10-22
EP1146872B1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
RU2298418C2 (ru) Комбинация по меньшей мере двух соединений, выбранных из групп антагонистов at1-рецептора или ингибиторов асе (ангиотензинпревращающий фермент), или ингибиторов hmg-coa-редуктазы (бета-гидрокси-бета-метилглутарил-кофермент-а-редуктаза)
KR20110107877A (ko) 유기 화합물의 조합제제
JP5968927B2 (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
KR100674053B1 (ko) 급성 심근경색의 치료를 위한 안지오텐신 ⅱ 수용체길항물질의 용도
US6767905B2 (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
AU724576B2 (en) A composition of enalapril and losartan
HK1100021A (en) Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
EP4574148A1 (en) Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension
Fogari et al. O-38: Effect of delapril and irbesartan on plasma PAI-1 and fibrinogen in hypertensive type 2 diabetic patients
Isenovic et al. O-37: Effect of vasopeptidase inhibition BMS189921 on PI3-kinase signaling in VSMCs
CA2498049A1 (en) At<sb>1</sb> receptor antagonists for preventing secondary strokes
AU2005209657A1 (en) Combination of at least two compounds selected from an AT1-Receptor antagonist or an ACE inhibitor or a HMG-CO-A reductase inhibitor group

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100119

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100119

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000